Table 1.
Demographic and baseline characteristics by ALC group
| Characteristic, n (%) | Eribulin (n = 500) | TPCa (n = 251) | ||
|---|---|---|---|---|
| ALC ≥ 1500/μl (n = 199) | ALC < 1500/μl (n = 301) | ALC ≥ 1500/μl (n = 92) | ALC < 1500/μl (n = 159) | |
| Geographical region | ||||
| North America/Western Europe/Australia | 106 (53) | 212 (70) | 51 (55) | 110 (69) |
| Eastern Europe | 66 (33) | 62 (21) | 29 (32) | 34 (21) |
| Latin America/South Africa | 27 (14) | 27 (9) | 12 (13) | 15 (9) |
| HER2 status | ||||
| Positive | 34 (17) | 48 (16) | 16 (17) | 23 (14) |
| Negative | 146 (73) | 221 (73) | 69 (75) | 121 (76) |
| Unknown | 19 (10) | 32 (11) | 7 (8) | 15 (9) |
| Prior capecitabine treatment | ||||
| Yes | 136 (68) | 228 (76) | 65 (71) | 122 (77) |
| No | 63 (32) | 73 (24) | 27 (29) | 37 (23) |
| ECOG performance status | ||||
| 0 | 87 (44) | 127 (42) | 40 (43) | 63 (40) |
| ≥ 1 | 110 (55) | 168 (56) | 51 (55) | 94 (59) |
| Age group | ||||
| < 65 years | 166 (83) | 242 (80) | 76 (83) | 120 (75) |
| ≥ 65 years | 33 (17) | 59 (20) | 16 (17) | 39 (25) |
| ER status | ||||
| Positive | 136 (68) | 195 (65) | 55 (60) | 114 (72) |
| Negative | 47 (24) | 95 (32) | 33 (36) | 39 (25) |
| Unknown | 16 (8) | 11 (4) | 4 (4) | 6 (4) |
| PgR status | ||||
| Positive | 103 (52) | 148 (49) | 43 (47) | 78 (49) |
| Negative | 68 (34) | 126 (42) | 37 (40) | 65 (41) |
| Unknown | 28 (14) | 27 (9) | 12 (13) | 16 (10) |
| HR status | ||||
| Positive | 141 (71) | 203 (67) | 61 (66) | 116 (73) |
| Negative | 38 (19) | 85 (28) | 26 (28) | 37 (23) |
| Unknown | 20 (10) | 13 (4) | 5 (5) | 6 (4) |
| Triple negative | ||||
| Triple negative | 27 (14) | 65 (22) | 21 (23) | 30 (19) |
| Non-triple negative | 172 (86) | 236 (78) | 71 (77) | 129 (81) |
| Site of disease | ||||
| Visceral disease | 160 (80) | 247 (82) | 74 (80) | 135 (85) |
| Nonvisceral disease | 36 (18) | 52 (17) | 17 (18) | 22 (14) |
| Number of organs involved | ||||
| ≤ 2 | 159 (80) | 208 (69) | 69 (75) | 95 (60) |
| > 2 | 37 (19) | 91 (30) | 22 (24) | 62 (39) |
| Number of prior chemotherapy regimens | ||||
| ≤ 3 | 111 (56) | 127 (42) | 44 (48) | 69 (43) |
| > 3 | 88 (44) | 172 (57) | 48 (52) | 89 (56) |
| Number of prior chemotherapy regimens for locally advanced or metastatic disease | ||||
| ≤ 3 | 165 (83) | 221 (73) | 66 (72) | 112 (70) |
| > 3 | 34 (17) | 80 (27) | 26 (28) | 46 (29) |
| Refractory to taxanesb | ||||
| Yes | 154 (77) | 249 (83) | 76 (83) | 127 (80) |
| No | 45 (23) | 52 (17) | 16 (17) | 32 (20) |
ALC absolute lymphocyte count, ECOG Eastern Cooperative Oncology Group, ER oestrogen receptor, HER2 human epidermal growth factor receptor-2, HR hormone receptor, PgR progesterone receptor, TPC treatment of physician’s choice
aTPC was defined as any single-agent chemotherapy, or hormonal or biological therapy, approved for the treatment of cancer
bDisease progression on or within 6 months of taxane treatment